Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.23.2
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2022
USD ($)
Licensing and other arrangements                    
Revenue from contracts with customers       $ 1,125 $ 525 $ 1,125 $ 3,275      
Novartis Note                    
Licensing and other arrangements                    
Reduction in debt obligation     $ 7,300              
Novartis International | License Agreement                    
Licensing and other arrangements                    
Agreement termination prior written notice period 180 days                  
Number of performance obligations | item 1                  
Cash payment received     17,700           $ 37,000  
Revenue from contracts with customers   $ 35,000 $ 25,000 0 $ 0 0 $ 0 $ 10,000 $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 480,000     410,000   410,000        
Royalty payment period, minimum 10 years                  
Contract assets       0   0       $ 0
Contract liabilities       0   0       0
Capitalized contract costs       $ 0   $ 0       $ 0